MARKET

APVO

APVO

Aptevo Therapeutics Inc
NASDAQ
2.940
-0.460
-13.53%
After Hours: 2.990 +0.05 +1.70% 19:55 08/14 EDT
OPEN
3.400
PREV CLOSE
3.400
HIGH
3.400
LOW
2.840
VOLUME
79.54K
TURNOVER
--
52 WEEK HIGH
48.78
52 WEEK LOW
2.840
MARKET CAP
4.46M
P/E (TTM)
-0.0144
1D
5D
1M
3M
1Y
5Y
1D
Aptevo Therapeutics Q2 EPS $(5.31) Beats $(6.16) Estimate
Benzinga · 13h ago
Aptevo Therapeutics Raises Capital Through Warrant-Induced Financing
TipRanks · 1d ago
Aptevo Therapeutics Closes Warrant Inducement Transaction, Issuing New Warrants For 1.27M Shares At $4.03 Per Share; Sells 861,708 Shares In $4.03 PIPE
Benzinga · 1d ago
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
Barchart · 2d ago
Weekly Report: what happened at APVO last week (0803-0807)?
Weekly Report · 4d ago
Weekly Report: what happened at APVO last week (0727-0731)?
Weekly Report · 08/03 09:13
Aptevo Therapeutics Unveils New Solid Tumor Strategy
TipRanks · 07/27 20:37
Reported Earlier: Aptevo Therapeutics Announces A New Solid Strategy Designed To Fight Cancer On Multiple Fronts; Files A Patent Application Covering A Proprietary Nectin-4 X PD-L1 Dual-Targeting Backbone Designed To Strengthen Aptevo's Oncology Pipeline
Benzinga · 07/27 20:24
More
About APVO
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.

Webull offers Aptevo Therapeutics Inc stock information, including NASDAQ: APVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APVO stock methods without spending real money on the virtual paper trading platform.